Biotechnology — Overview

Biotechnology is the use of living organisms, cells, or biological systems to develop products and technologies for human benefit. It spans agriculture, health, industry, and environment.

Colour Classification of Biotechnology

Colour Domain Examples
Red Medical / Pharmaceutical Gene therapy, vaccines, diagnostics, biopharmaceuticals, stem cells
Green Agricultural GM crops, biopesticides, biofertilisers, molecular breeding, biofortification
White Industrial Biofuels, enzymes, bioplastics, fermentation technology
Blue Marine / Aquatic Marine-derived pharmaceuticals, aquaculture biotechnology
Yellow Food / Nutrition Food processing, nutraceuticals, biofortification
Grey Environmental Bioremediation, waste treatment, biodegradation

India's Bioeconomy & BioE3 Policy

India's Bioeconomy Growth

Indicator Value
Bioeconomy size (2025) $195.3 billion (~5% of GDP)
Growth trajectory $10B (2014) → $80B (2020) → $165.7B (2024) → $195.3B (2025)
Growth rate (2025) 18% YoY
Growth trajectory $10B (2014) → $70B (2020) → $130B (2023) → $165.75B (2024) → $195.3B (2025)
Registered biotech startups 11,855 (1,780 new in 2025); India 3rd largest biotech hub in Asia-Pacific, 12th globally
Bio-incubators 95 BIRAC-supported centres
Key segments BioPharma ($64.5B), BioIndustrial ($90.2B), BioAgri, BioServices
Vision 2047 $1 trillion bioeconomy goal (Amrit Kaal)

BioE3 Policy (2024)

Feature Detail
Approved Cabinet approval on 24 August 2024
Full form Biotechnology for Economy, Environment and Employment
Goal $300 billion bioeconomy by 2030; high-performance biomanufacturing
Focus areas Bio-based chemicals; smart proteins; precision biotherapeutics; climate-resilient agriculture; carbon capture; marine and space research
Infrastructure Biomanufacturing & Bio-AI hubs; Biofoundries across India

BioE3 significance: Aligns with India's Net Zero and LiFE goals. Promotes circular bioeconomy and green growth, with job creation in tier-II/III cities through biomanufacturing hubs.


Genetic Engineering — Key Concepts

Term Meaning
GMO Genetically Modified Organism — has DNA altered using genetic engineering (transgenic: gene from different species)
Genome editing Precise modification of an organism's own DNA without introducing foreign genes (e.g., CRISPR)
Transgenic Contains gene(s) from another species (e.g., Bt cotton has gene from Bacillus thuringiensis)
Cisgenic Contains gene from a sexually compatible species — no foreign species involved
Gene silencing (RNAi) Switching off a specific gene without removing it
CRISPR-Cas9 Molecular "scissors" that cut DNA at precise locations; enables cheap, fast, accurate gene editing

Prelims Trap: GMOs and genome-edited organisms are NOT the same. GMOs contain foreign DNA (transgenic). Genome-edited organisms have their own DNA modified — no foreign genetic material is introduced. India's 2022 guidelines treat genome-edited plants (SDN-1 and SDN-2 categories) differently from GMOs, with a lighter regulatory pathway.


CRISPR-Cas9

How It Works

Feature Detail
Full form Clustered Regularly Interspaced Short Palindromic Repeats
Discovered by Jennifer Doudna & Emmanuelle Charpentier — Nobel Prize in Chemistry, 2020
Mechanism Guide RNA directs Cas9 enzyme to target DNA → Cas9 cuts the DNA → cell's repair mechanism edits it
Advantages Precise, cheap, fast, versatile (works in plants, animals, humans)
Limitations Off-target effects, mosaicism, ethical concerns in human germline editing

CRISPR Applications

Domain Application Example
Medicine Gene therapy for genetic disorders Casgevy — first CRISPR therapy, US FDA approved 2023 (sickle cell disease)
India (Medicine) Indigenous CRISPR gene therapy BIRSA 101 — CRISPR therapy for Sickle Cell Disease by CSIR-IGIB (with Serum Institute)
Agriculture Drought/salinity tolerance IARI's Pusa Rice DST1 (drought-salinity tolerant, SDN-1 edit, approved 2025)
Diagnostics Rapid pathogen detection FELUDA test (IGIB Delhi) — paper-based CRISPR COVID-19 test; 96% sensitivity, 98% specificity
Industrial Bio-based chemicals, biofuel feedstock Engineering microbes for biofuel production

India's CRISPR institutions: National Centre for Genome Editing & Training (NGETC) at Mohali; regulatory framework under National Guidelines for Gene Therapy (2019), CDSCO, NDCT Rules 2019.


GM Crops in India

Bt Cotton — India's Only Approved GM Crop

Feature Detail
Approved 2002 (Bollgard I); Bollgard II (two Bt genes: cry1Ac + cry2Ab) approved 2006
Technology Contains cry1Ac gene (and later cry2Ab) from Bacillus thuringiensis → produces Bt toxin → kills bollworm larvae
Adoption ~95% of India's cotton area is now Bt cotton
Impact Cotton production tripled (13.6 million bales in 2002 → 35.4 million bales by 2014); India became world's largest cotton producer
Controversy Pink bollworm resistance emerged (Gujarat, Maharashtra); seed monopoly concerns (Monsanto/Bayer); farmer suicide debate (correlation, not proven causation)

For Mains: The Bt cotton story is nuanced. Initial benefits were real — tripled yields, ~70% reduction in pesticide use against bollworm. But pink bollworm resistance development and dependence on proprietary seeds created new vulnerabilities. Use as a case study of technology adoption — benefits vs risks of monoculture and corporate dependency.

Bt Brinjal — Moratorium Since 2010

Feature Detail
Developed by Mahyco (Maharashtra Hybrid Seeds Company), Jalna
GEAC approval October 14, 2009 — cleared for commercial cultivation
Moratorium February 9, 2010 — Environment Minister Jairam Ramesh imposed indefinite moratorium
Reason No overriding food security urgency; opposition from 9 state governments; widespread public concern; brinjal is India's centre of origin (gene flow to wild relatives risk)
Current status Moratorium continues in India; however, Bangladesh has successfully cultivated Bt Brinjal commercially since 2014; 2020 — GEAC allowed confined field trials of indigenous Bt Brinjal varieties in 8 states

GM Mustard (DMH-11) — Ongoing Controversy

Feature Detail
Developed by Delhi University (Prof. Deepak Pental's team)
Technology Hybrid mustard using barnase-barstar gene system from Bacillus amyloliquefaciens
Yield advantage ~28% higher than national check variety
GEAC approval October 2022 — approved for environmental release
Supreme Court Split verdict (2024) — Justice Nagarathna invalidated; Justice Karol upheld. Referred to larger bench
Context India imports 55–60% of edible oil; DMH-11 could boost domestic production

Why it matters: DMH-11 could be India's second GM crop after 22 years. The debate combines science (safety), politics (anti-GM activism), economics (edible oil import burden), and federalism (states like Rajasthan oppose). A classic multi-dimensional Mains question.

Genome-Edited Crops — India's New Pathway (2025)

India approved its first genome-edited crop varieties in 2025 — NOT GMOs (no foreign DNA; SDN-1 category edit):

Variety Developed by Feature
Pusa Rice DST1 IARI, New Delhi Drought and salinity tolerance
DRR Dhan 100 IIRR, Hyderabad Improved grain quality and yield

India's 2022 genome editing guidelines exempt SDN-1 and SDN-2 edits from the full GMO regulatory process — creating a faster innovation pathway for crops that only modify the plant's own DNA.

Common Prelims Mistake: Bt Cotton is the ONLY commercially approved GM crop in India (since 2002). Bt Brinjal was approved but placed under moratorium (2010). GM Mustard got GEAC approval (2022) but is in legal limbo (SC 2024). Genome-edited crops (Pusa Rice DST1, DRR Dhan 100) are NOT GMOs — different regulatory category.


Regulatory Framework for GMOs in India

Key Laws

Legislation Role
Environment Protection Act, 1986 Umbrella law for GMO regulation
Rules for Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms/GMOs, 1989 Primary biosafety regulatory framework; notified under EPA 1986
Food Safety and Standards Act, 2006 Regulates GM food imports and labelling
Biological Diversity Act, 2002 Governs access to genetic resources

International: Cartagena Protocol on Biosafety

Feature Detail
Nature Supplementary agreement to the CBD — focused on safe transfer/handling/use of Living Modified Organisms (LMOs)
Adopted January 29, 2000 (Montreal); In force: September 11, 2003
India India is a Party
Key principle Advance Informed Agreement (AIA): Exporting country must notify importing country and get consent before first transboundary movement of an LMO for release into the environment
Precautionary principle Uncertainty about risks does not preclude taking preventive measures
Biosafety Clearing House (BCH) Online platform for exchanging biosafety information globally

India's Rules 1989 under EPA 1986 are broadly aligned with the Cartagena Protocol's requirements for risk assessment and information exchange.

Key Biosafety Risks

Risk Explanation
Horizontal gene transfer Transgenes may transfer to soil bacteria or wild plant relatives, creating ecological changes
Biodiversity impact Herbicide-tolerant GM crops may lead to monocultures, reducing agro-biodiversity
Allergenicity Foreign proteins in GM food could trigger allergic reactions
Resistance development Insects/weeds can develop resistance to Bt toxin or herbicide → "super-pests" and "super-weeds"
Cross-pollination GM pollen can contaminate non-GM and organic crops in neighbouring fields

Six-Tier Regulatory Structure

Body Level Role
RCGM (Review Committee on Genetic Manipulation) DBT Reviews research proposals involving GMOs
GEAC (Genetic Engineering Appraisal Committee) MoEFCC Apex body — approves environmental release of GMOs; renamed from "Approval" to "Appraisal" in 2010
IBSC (Institutional Biosafety Committee) Institution Monitors recombinant DNA research at each institution
SBCC (State Biotechnology Coordination Committee) State Monitors GMO use at state level
DLC (District Level Committee) District Monitors field trials at district level
RDAC (Recombinant DNA Advisory Committee) DBT Advises on recombinant DNA research policy

Prelims Fact: GEAC (under MoEFCC) is the apex approval body. RCGM (under DBT) handles research-stage approvals. Don't confuse the two. Agriculture is a State subject, but GM crop regulation is under EPA 1986 (Union law) — creating Centre-state tension.

Genome Editing Guidelines — SDN Categories (2022)

Category Description Regulatory Pathway
SDN-1 Small deletions/insertions; no foreign DNA Exempt from GMO regulations — treated like conventional breeding
SDN-2 Small changes using a DNA template from same/related species Lighter regulation than GMOs
SDN-3 Insertion of foreign DNA using CRISPR Regulated as full GMO (GEAC process required)

Medical Biotechnology

Gene Therapy

Aspect Detail
CRISPR-Cas9 Enables precise modification of DNA sequences — see CRISPR section above
India's first CRISPR therapy BIRSA 101 — indigenous CRISPR-based gene therapy for Sickle Cell Disease, developed by CSIR-IGIB; partner: Serum Institute of India
CRISPR Diagnostic Tata CRISPR test (FELUDA) — India's first CRISPR-based COVID-19 diagnostic; approved by DCGI
NGETC National Centre for Genome Editing & Training — Mohali, Punjab

Key Indian Vaccine Contributions

Vaccine Developer Type Significance
Covaxin (BBV152) Bharat Biotech + ICMR-NIV Pune Whole Virion Inactivated India's first fully indigenous COVID-19 vaccine; 81% efficacy in Phase 3
Covishield Serum Institute of India (SII) Recombinant Adenovirus Vector (AstraZeneca-Oxford) 70.42% efficacy; SII capacity ~250–275 million doses/month
Rotavac Bharat Biotech Live attenuated oral India's indigenous rotavirus vaccine; WHO prequalified
CERVAVAC Serum Institute of India Quadrivalent HPV India's first indigenous cervical cancer vaccine
ZyCoV-D Zydus Cadila DNA plasmid World's first DNA plasmid COVID-19 vaccine

Genome Sequencing Projects

Project Lead Agency Details
IndiGen CSIR (IGIB Delhi + CCMB Hyderabad) WGS of 1,029 Indians; identified 55.9 million SNVs; 32.23% unique to India
GenomeIndia Department of Biotechnology (DBT) WGS of 10,074 individuals from 83 distinct populations (99 communities); data opened by PM Modi on 9 January 2025; 135 million+ genetic variations identified

Why Genome India matters: Global genomic databases are dominated by European-ancestry data. Indians are genetically distinct and diverse. Without an Indian reference genome, precision medicine cannot work for India's population.


Biotech in Agriculture — Beyond GM Crops

Key Technologies

Technology Application Status in India
Biopesticides Microbial agents (Trichoderma, Beauveria, Bt spray) for pest control Widely used; growing market
Biofertilisers Nitrogen-fixing bacteria (Rhizobium), phosphate solubilisers Promoted under Soil Health Card scheme
Tissue culture Mass propagation of disease-free planting material Used for banana, potato, sugarcane
Marker-assisted selection (MAS) Using DNA markers to select desirable traits without genetic modification Used in rice drought-tolerant varieties
Biofortification Enhancing nutrient content through conventional breeding + biotech 71+ ICAR varieties released
Precision agriculture GPS, IoT sensors, drones, AI for data-driven farming Digital Agriculture Mission; Kisan Drone initiative
Vertical farming Indoor multi-layer crop production using hydroponics/LED lighting Startups in Mumbai, Bangalore, Delhi NCR

Biofortification — Key Indian Varieties

ICAR has released 71+ biofortified varieties across multiple crops:

Crop Variety Nutrient Enriched
Wheat Pusa Tejas (HI 8759) High protein (12%), iron (42 ppm), zinc (43 ppm)
Rice CR Dhan 315 High zinc
Maize Pusa Vivek QPM9 Improved High provitamin-A, lysine, tryptophan (Quality Protein Maize)
Pearl millet Dhanashakti High iron (70–75 mg/kg), zinc (35–40 mg/kg)
Sweet potato Bhu Sona High beta-carotene (provitamin-A)

Golden Rice (engineered with beta-carotene genes) approved in Australia, New Zealand, Canada — NOT approved in India. Remains a GM crops debate topic.


India's Biotech Institutional Framework

Department of Biotechnology (DBT)

Parameter Detail
Established 1986 — under Ministry of Science & Technology
Significance India was among the first countries to have a dedicated government body for biotechnology
Functions Funds R&D; promotes innovation; international collaborations; policy formulation
Focus Areas Healthcare, food security, environmental sustainability, energy security

BIRAC (Biotechnology Industry Research Assistance Council)

Parameter Detail
Type Not-for-profit Section 8 Public Sector Enterprise under DBT
Role Interface agency to strengthen emerging biotech enterprises; strategic research and innovation funding
Programmes BIG (Biotechnology Ignition Grant), SPARSH, PACE, SEED Fund, CRS
Bio-incubators 95 BIRAC-supported centres across India

National Biopharma Mission (NBM/i3)

Feature Detail
Outlay ₹1,500 crore (~$250 million); 50% co-funded by World Bank
Objective Accelerate biopharmaceutical development — from discovery to clinical trials to commercialisation
Scale 101 projects; 150+ organisations; 30 MSMEs supported
Focus Indigenous vaccines, biosimilars, diagnostics, biotherapeutics

India's Biopharmaceuticals — Global Position

Category India's Position
Vaccines Largest global vaccine producer by volume; Serum Institute of India = world's largest vaccine manufacturer (~1.5 billion doses/year)
Generic formulations ~20% of global generic medicine volume; largest supplier to WHO prequalified procurement
Biosimilars 100+ approved biosimilars in India; rapidly growing segment
Insulin Major producer — Biocon, Lupin, Wockhardt

One Health Approach

Aspect Detail
Concept Integrated approach recognising the interconnection between human health, animal health, and the environment
Relevance ~75% of emerging infectious diseases are zoonotic in origin (COVID-19, SARS, Nipah, Ebola)
India's Adoption NAP-AMR (2017) adopted One Health framework; inter-ministerial coordination between MoHFW, MoAHD, MoEFCC
Key Focus Areas Zoonotic diseases, food safety, antibiotic resistance, environmental health
Research Initiative ICMR-DBT-ICAR One Health Consortium (2021) — collaborative surveillance and research network

Exam Tip: For any UPSC answer on COVID-19, AMR, or avian flu, invoke the One Health framework. Key fact: ~75% of emerging infectious diseases are zoonotic. India's NAP-AMR (2017) explicitly adopted this approach. The institutional challenge is inter-ministerial coordination between MoHFW, MoAHD, and MoEFCC.


Antimicrobial Resistance (AMR)

Parameter Detail
NAP-AMR 1.0 Launched 19 April 2017; aligned with WHO Global Action Plan on AMR
NAP-AMR 2.0 Launched in 2024; updated strategy with human health, research, animal husbandry, and environment sectors
Global scale ~1.27 million deaths/year (Lancet, 2022); could cause 10 million/year by 2050
India's burden Among world's highest antibiotic consumers; ~119,000 MDR/RR-TB cases/year
ESKAPE pathogens Enterococcus, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter
Surveillance ICMR's AMR Surveillance Network (AMRSN); data to WHO's GLASS system
Root causes Over-the-counter antibiotics; irrational prescriptions; antibiotic overuse in agriculture/veterinary use

Ethical and Social Dimensions

Issue Discussion Points
Food safety Are GM foods safe? Scientific consensus: yes (approved varieties). Public perception differs
Farmer autonomy GM seeds are often patented → farmers cannot save seeds → corporate dependency
Biodiversity risk Gene flow from GM crops to wild relatives could create "superweeds"
Labelling India requires GM food labelling but enforcement is weak
Gene editing ethics Crops (widely accepted) → Animals (debated) → Human embryos (banned in most countries)
Access and equity Will biotech benefits reach smallholders or only corporate farms?
Biopiracy Exploitation of indigenous genetic resources without benefit-sharing

Biopiracy Landmark Cases

Turmeric Patent (1995–1997):

  • US Patent No. US5401504A granted to University of Mississippi Medical Centre (1995) for use of turmeric in wound healing
  • CSIR challenged it, proving turmeric's wound-healing use was documented in ancient Ayurvedic texts — not novel
  • USPTO revoked the patent in 1997 — one of the earliest successful biopiracy challenges

Neem Patent (1994–2005):

  • European Patent Office (EPO) granted Patent EP436257 to W.R. Grace & Co. and USDA on a neem-based fungicide (1994)
  • Dr. Vandana Shiva and activists filed opposition citing India's traditional neem use
  • EPO revoked the patent in May 2000; appeal confirmed final revocation in 2005

Traditional Knowledge Digital Library (TKDL)

Feature Detail
Established 2001 — joint initiative of CSIR and Ministry of AYUSH
Purpose Document India's traditional medicinal knowledge in machine-readable format accessible to global patent offices
Content ~0.9 million formulations from Ayurveda, Unani, Siddha, and Yoga texts
Languages Available in English, French, German, Spanish, and Japanese
Access Provided to patent examiners at USPTO, EPO, JPO, UKIPO, CIPO as prior art database
Impact Cited in 200+ patent examination proceedings; prevented grant of patents on traditional Indian knowledge

TKDL represents India's "defensive protection" strategy — documenting traditional knowledge as prior art to prevent others from patenting it, rather than patenting it (which may not meet novelty criteria).


Important for UPSC

Prelims Focus Areas

  • Bt Cotton: only GM crop approved in India (2002); GEAC is apex body under MoEFCC (not MoA or DBT)
  • Bt Brinjal moratorium: February 2010, Jairam Ramesh; moratorium continues
  • GM Mustard (DMH-11): GEAC approved October 2022; SC split verdict 2024; legal limbo
  • Genome-edited crops (2025): Pusa Rice DST1 + DRR Dhan 100 — NOT GMOs (SDN-1 category)
  • CRISPR: Nobel Prize Chemistry 2020 — Doudna & Charpentier; FELUDA = Tata + CSIR-IGIB
  • SDN-1/SDN-2/SDN-3 categories for genome editing
  • DBT established 1986; BIRAC = PSE under DBT
  • BioE3 Policy: Cabinet August 24, 2024; $195.3B bioeconomy (2025)
  • NAP-AMR launched 2017; updated 2024; ESKAPE pathogens
  • GenomeIndia: 10,074 individuals, 83 populations; IndiGen: 1,029 individuals
  • Biofortified varieties: Pusa Tejas (wheat), Dhanashakti (pearl millet), CR Dhan 315 (rice)
  • BIRSA 101: India's first indigenous CRISPR gene therapy (CSIR-IGIB + SII)

Mains Dimensions

Dimension Angle
Science & Tech (GS3) CRISPR applications (agriculture + medicine); GM crop debate; genome sequencing for precision medicine; biofortification as nutrition solution
Governance (GS2) Regulatory framework for GM crops — adequacy, Centre-state tensions; GEAC vs RCGM; gene therapy oversight
Economy (GS3) India's bioeconomy ($195.3B, 2025); BioE3 Policy; pharma sector — "Pharmacy of the World"; biotech start-up ecosystem
Social Issues (GS1/GS2) Health equity (UHC through PMJAY); tribal health and sickle cell disease (BIRSA 101)
Ethics (GS4) Ethics of gene editing in humans; GM crop safety vs food security; clinical trial ethics; informed consent; biopiracy
Environment (GS3) One Health approach; AMR and environment; biosafety concerns with GM organisms; gene drives for invasive species

Interview Angles

  • Should India allow GM food crops beyond Bt Cotton? What's the right balance between food security and biosafety?
  • Gene editing: where should India draw the ethical line? Crops vs animals vs human germline?
  • India's TKDL model — can traditional knowledge be effectively protected in the IP regime?
  • Is India's bioeconomy growth ($195B) benefiting small farmers and rural populations?
  • One Health: is India's institutional structure adequate for cross-sectoral health governance?


Vocabulary

Genome

  • Pronunciation: /ˈdʒiː.nəʊm/
  • Definition: The complete set of genetic material (DNA or, in some viruses, RNA) present in a cell or organism, containing all the information needed for that organism's development and function.
  • Origin: Coined by German botanist Hans Winkler in 1920, as a blend of German Gen ("gene") and Chromosom ("chromosome").

CRISPR

  • Pronunciation: /ˈkrɪs.pər/
  • Definition: An acronym for Clustered Regularly Interspaced Short Palindromic Repeats, a gene-editing technology derived from a bacterial defence system that enables precise modification of DNA sequences in living organisms.
  • Origin: The acronym was proposed by Francisco Mojica and Ruud Jansen in 2001; the gene-editing application using CRISPR-Cas9 was developed by Jennifer Doudna and Emmanuelle Charpentier (Nobel Prize in Chemistry, 2020).

Transgenic

  • Pronunciation: /trænzˈdʒɛn.ɪk/
  • Definition: Describing an organism whose genome has been altered by the introduction of one or more genes from a different species using genetic engineering techniques.
  • Origin: From Latin trans- ("across") + Greek genos ("race, kind") + -ic; coined in the 1980s to describe organisms carrying foreign genetic material.

Biopesticide

  • Pronunciation: /ˌbaɪoʊˈpɛstɪˌsaɪd/
  • Definition: A pest-control agent derived from natural biological sources — such as bacteria, fungi, viruses, or plant extracts — used as an environmentally safer alternative to synthetic chemical pesticides.
  • Origin: Compound of Greek bios ("life") + Latin pestis ("plague, pest") + -cide (from Latin caedere, "to kill").

Biofertiliser

  • Pronunciation: /ˌbaɪoʊˈfɜːrtɪˌlaɪzər/
  • Definition: A substance containing living micro-organisms — such as nitrogen-fixing bacteria (Rhizobium) or phosphate-solubilising fungi — that, when applied to seeds, plant surfaces, or soil, enhances nutrient availability and promotes plant growth.
  • Origin: Contraction of biological fertiliser; bio- from Greek bios ("life").

Key Terms

Genetic Modification

  • Pronunciation: /dʒəˈnɛt.ɪk ˌmɒd.ɪ.fɪˈkeɪ.ʃən/
  • Definition: The deliberate alteration of an organism's DNA using laboratory techniques — including insertion of foreign genes (transgenic), deletion of existing genes, or site-specific modification using CRISPR-Cas9. The key regulatory distinction: traditional GM (foreign DNA, full GEAC process) vs genome editing SDN-1/SDN-2 (no foreign DNA, lighter regulation).
  • Context: Bt cotton (cry1Ac gene) is India's only approved GM crop since 2002. Bt Brinjal was approved by GEAC October 2009 but placed under moratorium February 2010 (Jairam Ramesh). GM Mustard (DMH-11) received GEAC approval October 2022 but faces SC legal challenge (split verdict 2024). India's first genome-edited crops (Pusa Rice DST1, DRR Dhan 100) approved 2025 — SDN-1 category, no foreign DNA.
  • UPSC Relevance: GS3 (Science & Technology). Know SDN-1/SDN-2/SDN-3 categories; GEAC under MoEFCC is apex GM approval body; RCGM under DBT handles research stage. Mains: GM crops debate, biopiracy (TKDL, Neem/Turmeric), Centre-state tensions, food security vs biosafety.

Bt Cotton

  • Pronunciation: /ˌbiː ˈtiː ˈkɒtən/
  • Definition: India's only approved GM crop (since 2002), containing the cry1Ac gene from Bacillus thuringiensis that produces insecticidal proteins toxic to bollworm larvae. Covers ~95% of India's cotton area; tripled cotton production by 2014. Controversies: pink bollworm resistance emerged; seed monopoly concerns (Monsanto/Bayer); farmer suicide debate (correlation only, not proven causation).
  • UPSC Relevance: GS3. Prelims: approved 2002, only approved GM crop, GEAC under MoEFCC. Mains: Use as case study for technology adoption — initial success (tripled production, ~70% pesticide reduction) vs emerging challenges (resistance, dependency). Centre-state regulation tensions.

GM Crops Regulation

  • Pronunciation: /ˌdʒiː ˈɛm krɒps ˌrɛɡjuˈleɪʃən/
  • Definition: India's six-tier framework: IBSC (institution) → RCGM (DBT) → RDAC (DBT policy) → SBCC (state) → DLC (district) → GEAC (apex, MoEFCC). Primary law: GMO Rules 1989 under EPA 1986. GEAC renamed from "Approval" to "Appraisal" Committee in July 2010. SDN-1/SDN-2 genome-edited plants exempt from full GMO process per 2022 SOPs.
  • UPSC Relevance: GS3 (Governance/Science). Know GEAC is under MoEFCC not DBT. Mains: Centre-state friction (agriculture = State subject; GM regulation = Union law), adequacy of India's regulatory framework, GM Mustard SC case 2024.

Stem Cell Therapy

  • Pronunciation: /stɛm sɛl ˈθɛr.ə.pi/
  • Definition: Regenerative medicine using stem cells to repair or replace diseased tissues. Types: embryonic stem cells (pluripotent), adult/somatic stem cells (multipotent), and induced pluripotent stem cells (iPSCs — adult cells reprogrammed by Shinya Yamanaka, Nobel 2012). India's regulatory framework: ICMR-DBT National Guidelines for Stem Cell Research (1st 2007, revised 2017). Reproductive cloning prohibited; therapeutic cloning permitted under oversight.
  • UPSC Relevance: GS3. Prelims: types of stem cells; iPSC Nobel 2012 (Yamanaka + Gurdon). Mains: ethical concerns (embryonic SC research involves embryo destruction), India's regulatory framework, therapeutic applications (bone marrow transplants, potential for Parkinson's, diabetes).

Current Affairs Connect

Resource Link
Science & Tech News Ujiyari — Science & Tech News
Editorials Ujiyari — Editorials

Sources: pib.gov.in, dbtindia.gov.in, birac.nic.in, mohfw.gov.in, nhm.gov.in, nha.gov.in, moefcc.gov.in, ncdc.mohfw.gov.in, india.gov.in, Lancet 2022 (AMR data), ICAR biofortification data.